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Abstract
Background: Readthrough fusions across adjacent genes in the genome, or transcription-induced chimeras (TICs),
have been estimated using expressed sequence tag (EST) libraries to involve 4-6% of all genes. Deep transcriptional
sequencing (RNA-Seq) now makes it possible to study the occurrence and expression levels of TICs in individual
samples across the genome.
Methods: We performed single-end RNA-Seq on three human prostate adenocarcinoma samples and their
corresponding normal tissues, as well as brain and universal reference samples. We developed two bioinformatics
methods to specifically identify TIC events: a targeted alignment method using artificial exon-exon junctions within
200,000 bp from adjacent genes, and genomic alignment allowing splicing within individual reads. We performed
further experimental verification and characterization of selected TIC and fusion events using quantitative RT-PCR
and comparative genomic hybridization microarrays.
Results: Targeted alignment against artificial exon-exon junctions yielded 339 distinct TIC events, including 32
gene pairs with multiple isoforms. The false discovery rate was estimated to be 1.5%. Spliced alignment to the
genome was less sensitive, finding only 18% of those found by targeted alignment in 33-nt reads and 59% of
those in 50-nt reads. However, spliced alignment revealed 30 cases of TICs with intervening exons, in addition to
distant inversions, scrambled genes, and translocations. Our findings increase the catalog of observed TIC gene
pairs by 66%.
We verified 6 of 6 predicted TICs in all prostate samples, and 2 of 5 predicted novel distant gene fusions, both
private events among 54 prostate tumor samples tested. Expression of TICs correlates with that of the upstream
gene, which can explain the prostate-specific pattern of some TIC events and the restriction of the SLC45A3-ELK4
e4-e2 TIC to ERG-negative prostate samples, as confirmed in 20 matched prostate tumor and normal samples and
9 lung cancer cell lines.
Conclusions: Deep transcriptional sequencing and analysis with targeted and spliced alignment methods can
effectively identify TIC events across the genome in individual tissues. Prostate and reference samples exhibit a
wide range of TIC events, involving more genes than estimated previously using ESTs. Tissue specificity of TIC
events is correlated with expression patterns of the upstream gene. Some TIC events, such as MSMB-NCOA4,
may play functional roles in cancer.
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Readthrough gene fusions, or transcription-induced chi-
meras (TICs), occur when consecutive genes on a gen-
ome strand are spliced together. Their existence was
first reported experimentally in isolated cases [1-4], and
later surveyed computationally using analyses of
expressed sequence tags (ESTs). Two different EST-
based studies have been carried out to date. In one
study [5], researchers clustered ESTs and then aligned
these clusters to the genome, looking for alignments
that crossed gene boundaries. The other study [6]
involved identification of potential tandem gene pairs
a n ds o u g h tE S T st h a ts p a n n e db o t hg e n e si nap a i r .
These studies indicate that at least 4-6% of genes in the
genome may be involved in TIC formation, although
their prevalence was found to be generally low.
Nevertheless, in some cases, TICs appear to be
expressed highly and generate functional protein pro-
ducts, with possible implications in cancer. For example,
the HHLA1-OC90 TIC is expressed highly in teratocar-
cinoma cell lines [7], while the CD205-DCL1 TIC is
expressed in Hodgkin lymphoma cell lines [8]. A TIC
between the oncogene RBM14 and RBM4 generates a
fusion protein called transcriptional coactivator CoAZ
[9]. Another TIC between RBM6 and RBM5 is found in
several cancer tissues and cell lines, but not in non-
tumor tissues, and is associated with larger breast tumor
sizes [10]. Likewise, a TIC between exon 4 of SLC45A3
and exon 2 of ELK4 found in prostate adenocarcinomas
[11] has an erythroblast transformation-specific (ETS)
oncogene family member as its downstream gene. In
addition to the e4-e2 TIC isoform, which was observed
specifically in ERG-negative prostate cancer samples,
another isoform e1-e2 has been observed in both pros-
tate cancer and benign prostate tissue, and found to be
regulated by androgen levels [12].
Although EST-based studies have identified over 300
distinct TIC events so far, these events are spread over
the multiple RNA libraries from which the ESTs were
derived. Accordingly, an EST-based study cannot reveal
the extent or diversity of TIC occurrences in an indivi-
dual sample. The ability to study TICs in a single sam-
ple would facilitate the discovery of associations
between TIC events and phenotypic traits, such as pro-
pensity for particular cancer types or other diseases, or
sensitivity to specific treatments.
One clue to the occurrence of TIC events within sam-
ples comes from RACE (rapid amplification of cDNA
ends) studies, in which specifically targeted transcript
regions are extended upstream (5’ RACE) or down-
stream (3’ RACE) and then aligned to genomic tiling
arrays to reveal their gene structure [13]. In one large-
scale 5’ RACE study covering 1% of the genome targeted
by the Encyclopedia of DNA Elements (ENCODE) pro-
ject across 12 human tissues and 3 cell lines, an
upstream extension indicative of a TIC event was found
in 136 of the 410 loci studied [14].
Because RACE can assay only specific transcripts
selected in advance, it can miss TIC events that may
predominate or have functional relevance in a particular
sample. In contrast, a genome-wide study of transcrip-
tional phenomena in individual tissues is now possible
with the recent advent of deep, or next-generation,
sequencing technology. Such technology provides a sam-
pling of the entire range of transcriptional phenomena
in single tissues, by generating large volumes of short
reads of 30-100 nt [15]. However, analyzing such RNA-
Seq data to study TICs poses its own set of unique chal-
lenges. Although many studies to date have analyzed
RNA-Seq data for the tasks of expression, sequence
polymorphisms, and even gene fusions in general, none
so far have tried to specifically detect TIC events, and
previous studies have reported relatively few such
events. Four TICs were reported in targeted sequencing
analysis of K562 [16]. Another study of the VCaP and
K562 cell lines and the HBR and UHR samples using
paired-end reads reported 76 fusion events [17], of
which 23 appear to be TICs. A recent study of 25 pros-
tate cancer samples [18] using an algorithm called
FusionSeq [19] identified 11 readthrough fusion candi-
dates and experimentally verified 9 of them.
In this study, we explore two different methods for
detecting TICs in RNA-Seq data with high sensitivity.
One method involves a targeted alignment approach
where reads are aligned to a set of artificial exon-exon
target sequences constructed in advance. Such a tar-
geted alignment strategy has been highly effective in
studying the extent of intragenic alternative splicing in
the human genome, even in short reads of only 32 nt
[20-23]. But for intergenic splicing events in general, tar-
geted alignment is not applicable as a computational
strategy, because it is infeasible to generate all possible
exon-exon pairs over the human genome. In this paper,
we demonstrate that a targeted alignment approach is
nevertheless well suited for sensitive detection of TIC
events across the universe of possible exon-exon pairs of
this type.
Our other method is to align the reads to a reference
genome using a program that can split an individual
alignment to different locations in a genome. Various
such alignment tools or pipelines have been developed
for detecting spliced reads in short read data within
local regions of a genome, including QPALMA [24] and
TopHat [25]. Other recent programs, including Split-
Seek [26] and our own program GSNAP [27], provide
the additional capability of finding splicing events
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tions in a genome. The spliced alignment approach is
more general, because it can identify novel or distant
gene fusions not enumerable by a targeted alignment
approach. However, it is less sensitive, especially when
reads are very short, because it requires enough material
on both sides of the exon-exon junction for accurate
alignment. For example, GSNAP requires at least 14 nt
on both sides of the exon-exon junction to to find a
novel spliced alignment, without any further assistance,
such as a user-provided database of known splice sites.
In most cases, at least 20 nt are required to uniquely
identify a genomic location in the unmasked part of the
human genome [28], and even more if mismatches,
SNPs, or indels are allowed. Therefore, spliced align-
ment is generally effective only for reads having exon-
exon junctions in their middle regions, away from the
14-20 nt margins at their ends.
Another strategy that is applicable when paired-end
reads are available is to align the two ends separately
and look for cases where the two ends align to different
gene transcripts. Studies suggest that a paired-end strat-
egy has greater sensitivity for finding gene fusions [17],
and the FusionSeq algorithm [19] is based on paired-
end reads. However, the single-end data in our study
precluded this approach.
In this paper, we show that both the targeted align-
ment and spliced alignment approaches can be used in
complementary ways to study TICs and gene fusions in
individual cancer and normal samples assayed by deep
transcriptional sequencing. We applied both methods to
sets of single-end reads that we obtained by sequencing
the transcriptomes of three primary human prostate
adenocarcinomas (denoted by T1, T2, and T3) and their
matched normal samples (N1, N2, and N3), as well as
the human brain reference (HBR) and universal human
reference (UHR) samples used in the Microarray Quality
Control (MAQC) project [29,30]. One of the adeno-
carcinomas, T1, is ETS-negative, and the remaining ade-
nocarcinomas are ETS-positive, with the positive
expression of an ETS family member conferred by a
TMPRSS2-ERG gene fusion [31]. We also implemented
filtering methods that are necessary to remove possible
false positive alignments due to gene families or other
homologous genes. After filtering, we were still left with
sequence-based support for a large number of TIC
events among our samples, which afforded us an oppor-
tunity to further characterize the phenomenon.
RNA-Seq data can provide not only splicing informa-
tion but also information about expression levels, which
can help us understand the expression patterns of TICs.
Although experimental evidence indicates that some
TICs are expressed ubiquitously over different tissues,
while others are expressed specifically in particular
tissues [6], the mechanism for these varying expression
patterns has not been well studied.
Expression information can also provide clues about
the mechanism of TIC formation. The prevailing
hypothesis is that TIC events represent a type of tran-
scriptional “leakage,” in which termination of transcrip-
tion fails for the upstream, or 5
’ gene, resulting in the
two adjacent 5
’ and 3
’ genes existing on a single tran-
script [6]. The splicing machinery then acts on this tran-
script to give rise to the TIC. However, in contrast to
this cis- m e c h a n i s m ,s o m ee v i d e n c eh a sp o i n t e dt oa
trans-mechanism, where genes on two separate tran-
scripts are spliced together. The trans-mechanism has
been demonstrated both for genomically distant genes
[32] and for adjacent genes involved in TICs [9]. We
therefore seek evidence related to TIC formation by
integrating expression and splicing analyses from our
RNA-Seq data, and from supporting experiments.
Results
Targeted alignment method
Based on 27,157 well-annotated RefSeq transcript align-
ments to the human genome, we identified 2,470,383
exon-exon junctions between same-strand transcripts
that spanned a potential intron of 200,000 bp or less.
We also identified 1,856,519 possible intragenic exon-
exon junctions by taking all pairs of exons within a
given transcript, regardless of distance. Each of these
junctions was extended by 80 nt on each side and used
as targets for the alignment of reads. An alignment
therefore supports a given exon-exon junction when it
crosses the midpoint by a certain overhang. Longer
overhang requirements provide greater specificity, while
shorter ones are more sensitive.
Using an overhang of 11 nt, intragenic splicing was
supported by 2-4% of 33-nt reads and by 6-11% of 50-nt
reads (Table 1), showing that longer reads provided sig-
nificantly more raw material for identifying splicing
events. For TIC splicing, a threshold of 8 nt yielded a
u n i q u ea l i g n m e n tt oaT I Ct a r g e ti na b o u t1i n3 0 , 0 0 0
reads. At 11 nt, the frequency dropped to 1 per 40,000-
120,000 reads. Overall, we found evidence for TIC spli-
cing to be rare in RNA-Seq data.
To achieve sensitivity with such few reads, we started
with the set of TIC alignments with an overhang of 8
nt, and used a clustering method to to obtain specificity.
C l u s t e r i n ga l l o w e dag i v e nT I Ce x o n - e x o nj u n c t i o nt o
be supported by the entire collection of alignments in
demonstrating a sufficient overhang. Before clustering,
though, we filtered our set of TIC alignments to remove
those that corresponded to intragenic alternate splicing
events. These spurious TIC alignments arose because
they spanned a particular splice combination across two
RefSeq transcripts for the same gene that was not
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ing process eliminated 3702 (29%) out of 12,400 putative
TIC alignments.
In the clustering process, we took the remaining 8698
TIC-aligning reads over all samples, grouped them
according to their exon-exon junction, and created a
multiple sequence alignment for the cluster, resulting in
608 clusters. To reduce the incidence of false positives
due to poor alignments, we implemented a filtering
method based on the consistency of matches and mis-
matches on both sides of the exon-exon junction, essen-
tially requiring that at least one read have a match to the
genome at all 11 bp on both sides of the junction. Our
filtering criteria were designed to eliminate false align-
ments, but still accommodates e q u e n c i n ge r r o r s ,w h i c h
can occur at a rate of 1% or more in short read data.
The filtering step eliminated 137 (23%) of the clusters
to leave 471 TIC candidates supported by 3373 TIC
alignments. However, the number of supporting reads
was not evenly distributed over the different candidates.
In particular, 2195 (65%) TIC alignments supported 12
candidates corresponding to various pairs of exons from
the human leukocyte antigen (HLA) genes, namely, from
HLA-B to HLA-C (7 intergenic splicing candidates), from
HLA-DRB1 to HLA-DRB3 (1 candidate), and from HLA-
G to HLA-A (4 candidates). Because these genes are
highly polymorphic and share sequence similarity with
one another (e.g., 92% sequence identity between HLA-B
and HLA-C), such TIC candidates most likely represent
misalignment due to sequence errors or polymorphisms
rather than true TIC events. Another example of likely
false positives were 15 TIC candidates supported by 41
TIC alignments involving pairings of the metallothionein
family members MT1A, MT1B, MT1E, MT1F, MT1 H,
MT1 M, MT1X, MT2A,a n dMT3.
To eliminate such cases of false positives due to
homologous genes, we implemented another filtering
step based on sequence similarity among the TIC splice
and its component 5’ and 3’ genes. Among the TIC can-
didates eliminated were 26 TIC candidates involving
pairs of various zinc finger proteins; 7 TIC candidates
involving pairs of keratins KRT5, KRT6A, KRT8, KRT14,
KRT17, KRT31, KRT32, KRT76, KRT77, KRT78, KRT81,
and KRT83; and 4 TIC candidates involving pairs of kal-
likreins KLK2, KLK3, KLK9,a n dKLK11.O v e r a l l ,o u r
homology filtering step eliminated 32% of the TIC can-
didates to leave a final set of 339 TIC events supported
by 822 alignments (Additional files 1 and 2).
To assess the false discovery rate (FDR) of our analysis
pipeline, we modified our set of artificial exon-exon
junctions by removing 5 nt from both sides of the junc-
tion, and performed the same alignment and filtering
steps against these modified junctions. This method was
previously used in determining an FDR rate for alterna-
tive splicing predictions [20]. This control experiment
gave a total of 5 putative TIC candidates, yielding an
estimated FDR rate of 5/339 = 1.5%.
Of the 822 surviving TIC-aligning reads, 459 (56%) came
from the MAQC samples sequenced at 50-nt read lengths,
229 (28%) from the N1 and N2 samples sequenced at 50-
and 75-nt read lengths, and the remaining 134 (16%) from
the prostate samples sequenced at 33-nt read lengths. This
skewed distribution is likely to be due largely to the utility
of longer read lengths in detecting TICs, rather than the
underlying frequency of TIC events in the samples.
Among the 339 TIC events, two-thirds (212) were
supported by a single alignment and one-third (127)
were supported by multiple alignments. The TIC events
with the largest numbers of supporting reads were
PMF1-BGLAP e4/5-e2/4 (55 reads), AZGP1-GJC3 e2/4-
e2/2 (41 reads), BPTF-KPNA2 e9/30-e2/11 (23 reads),
RBM14-RBM4 e1/3-e2/4 (18 reads), and C15orf38-
AP3S2 e5/6-e2/6 (16 reads). (In this notation, we indi-
cate the number of exons in the gene, so “e4/5” denotes
the fourth exon out of five in the gene.)
The 339 TIC events showed several cases of multiple
TIC isoforms across 302 distinct gene pairs. About 11%,
or 32, of the gene pairs had multiple isoforms, with the
pair PLEKHO2-ANKDD1A having 4 isoforms (Figure 1A),
and three pairs, KIAA1984-C9orf86, GCSH-C16orf46, and
RBM14-RBM4, each having three isoforms. In almost all
cases of multiple isoforms, the isoforms had one splice site
Table 1 Results of alignment to intragenic and TIC targets
Overhang 8 Overhang 11
Length Total reads Intragenic Pct TIC Pct Intragenic Pct TIC Pct
T1 33 30,797,857 966,447 3.1 1329 .0043 655,926 2.1 338 .0011
T2 33 32,029,444 1,216,580 3.8 1104 .0034 826,518 2.7 272 .0008
T3 33 65,479,803 2,171,327 3.3 2499 .0038 1,476,928 2.3 860 .0013
N1 50,75 33,509,416 3,862,551 11.5 1229 .0037 3,391,849 10.1 925 .0027
N2 50 33,125,582 2,925,272 8.8 945 .0029 2,449,004 7.4 559 .0017
N3 33 30,987,067 1,190,231 3.8 1213 .0039 810,039 2.6 507 .0016
HBR 50 53,238,798 3,487,753 6.6 1704 .0032 2,930,589 5.5 960 .0018
UHR 50 59,561,348 5,301,691 8.9 2377 .0040 4,445,658 7.5 1335 .0022
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that splice site. The finding of multiple TIC isoforms has
been reported experimentally in isolated cases, but not in
previous EST-based surveys, which were not designed to
identify them.
Comparison with existing databases
The AceView database [33] is intended to store all
observed alternative splicing events in various genomes.
Manual examination of our TIC events on the AceView
Web site indicated that many are annotated as complex
loci, those in which a protein product is generated from
the fusion of the two genes, although the two genes may
still have distinct expression. We performed a search of
AceView for all of our TIC events and found that 88
( 2 6 % )w e r ep r e v i o u s l yi d e n t i f i e di nt h a td a t a b a s e .T h e
32 gene pairs with multiple isoforms were more often
listed in AceView as complex loci, with 40% (13) having
that annotation.
We compared our TIC events with the 212 EST-based
events reported by Akiva and colleagues, and found that
37 fusion events (11%) were identified with the same
splice sites, with another 39 gene pairs (12%) identified
with a different pair of splice sites. In comparison with
the 176 human TIC events reported by Parra and collea-
gues, these values were 14 (4%) and 16 (5%), respec-
tively. A comparison among the EST-based surveys and
our study at the gene pair level shows relatively little
overlap among the three studies (Figure 2A). Therefore,
our RNA-Seq study increases the catalog of gene pairs
with observed TIC events by 66%.
We also scanned genomic alignments of all GenBank
ESTs to find support for our TIC events, and found
supporting ESTs for 100 events (29%), which covered 82
of those found in AceView plus an additional 18 events.
In addition, 12 of our TIC events (4%) were also found
by Maher and colleagues in their analysis of the HBR
and UHR samples. A comparison of our findings with
the FusionSeq-based prostate cancer study [18] showed
that we had reads for 6 of their 11 candidates, including
VMAC-CAPS, which was not otherwise supported by
external evidence. However, one of their candidates,
ZNF649-ZNF577, was removed by our conservative
homology filtering step, because we found that the two
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Figure 1 Complex isoforms observed in transcription-induced chimeras. TIC splicing events are shown by dashed arrows, labeled with
splice distance and samples or ESTs with supporting alignments. Standard splicing is shown by solid lines. (A) Multiple isoforms observed for
PLEKHO2-ANKDD1A TIC in the human brain reference (HBR) and universal human reference (UHR) samples. (B) Direct TIC splicing and TICs with
multiple forms of intervening exons (labeled IE) for VAMP8-VAMP5, all observed in a single prostate sample N1. Shaded box represents an
intervening exon found previously [5], but not in this study. (C) TIC with an intergenic exon between ARMCX5 and GPRASP2, all observed in N1.
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Page 5 of 22genes share a region with 42 matches in a window of
size 50. Altogether, 128 (38%) of our TIC events had
support from another database or study. We noted a
difference in support between our candidates that had a
single read finding and those that had multiple reads,
with external support for only 59 (28%) of the 212 sin-
gle-read candidates, but for 69 (54%) of the 127 multi-
ple-read candidates.
Characteristics of TIC events
Among the 127 events supported by multiple align-
ments, 95 (74%) had reads from different samples. If we
consider the prostate tumor and normal samples as a
single tissue type, then 79 events (62%) had support
from two or more different tissue sources in prostate,
brain, and universal reference. The distribution of tissue
sources among these multiply-supported TIC events
supports a ubiquitous expression pattern for some
events, with others that may potentially be brain- or
prostate-specific (Figure 2B).
Distances of TIC splices showed an exponential distri-
bution (Figure 2D), consistent with an earlier study [5].
Approximately one-fourth had distances of less than
12,000 bp, one-half less than 26,000 bp, and three-
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Figure 2 Characteristics of TIC events. (A) Comparison of TIC gene pairs found in previous EST-based surveys and those found by RNA-Seq in
this study. (B) Distribution of TIC events across tissues. Only TIC events with multiple supporting reads are included. HBR = human brain
reference, UHR = universal human reference. (C) Coding potential of TIC events. The label “Full CDS” indicates that the coding region (CDS)
extends from the original transcription start site (TSS) of the 5’ gene and to the original stop codon of the 3’ gene; “3’ shift” signifies a frameshift
in the 3’ gene; “New TSS” indicates that the TIC breakpoint occurs before the original TSS of the 5’ gene and a new TSS is predicted from the
longest open reading frame; “TLE” indicates that termination occurs in the last exon of the transcript; and “PTC” indicates premature termination
codon, subjecting the transcript to nonsense-mediated decay. (D) Distribution of TIC splice distances. (E) Distribution of splice distances in the
artificial exon-exon junctions. (F) Predicted effect on domains. Separate results are presented for TICs having a PTC, or having a TLE despite a
new TSS or 3
’ frameshift, or having a full CDS. Each pair of bars show the effect on the 5’ (left) and 3’ (right) domains. “ND” indicates that no
domain was originally present in the 5
’ or 3
’ gene; “Null” indicates no intersection of the predicted TIC domains with the original domains;
“Subset” indicates that at least one, but not all domains were preserved in the TIC; and “Cover” indicates all domains were preserved. (G)
Distribution of expression levels in 5
’ genes with observed TICs downstream compared to those without. (H) Distribution of expression levels in
3
’ genes with observed TICs compared to those without. For panels F and G, distributions are taken over genes with at least one observed
intragenic splice in a given sample and with a potential TIC exon within 200,000 bp in the downstream or upstream direction, respectively.
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than the median of 8500 bp reported in the previous
study, but that study measured the distance between
genes, rather than the distance between spliced exons.
When we computed the intergenic distance for each TIC,
we obtained a comparable median of 8866 bp. To rule
out the possibility that the preference of TICs for shorter
splice distances was due to our underlying set of artificial
exon-exon junctions, we compiled a comparative distri-
bution over the artificial splice distances (Figure 2E),
which shows a much different distribution favoring
longer distances uniformly above 40,000 bp.
TIC splices occurred predominantly between the last
donor site of the 5’ gene and the first acceptor site of
the 3’ gene. In our set of readthrough fusions, this spli-
cing pattern between the (n - 1) and +2 exon repre-
sented 54% of the cases, somewhat more than the 44%
seen in a previous study [5]. Exons upstream of the
(n - 1) exon spliced with the +2 exon 25% of the time,
while the (n - 1) exon spliced with exons downstream of
the +2 exon 10% of the time. Therefore, alternate
choices were more likely to occur with the donor site
than with the acceptor site. In 12% of the cases, a TIC
event spliced both an upstream exon other than (n -1 )
and a downstream exon other than +2.
To determine whether our TICs were likely to generate
a functional protein, we computed a probable coding
sequence (CDS) for each TIC (Figure 2C). For TIC break-
points that occur after the transcription start site (TSS) of
the 5’ gene, we expect that the TSS should be preserved,
serving as the start of the reading frame for the rest of the
TIC transcript. Starting from the original TSS, the reading
frame was preserved for the 3’ gene in 120 cases (35%),
ending at the original stop codon, and frameshifted in the
other 193 cases (57%) with a post-TSS breakpoint. In the
remaining 26 cases (8%) with a pre-TSS breakpoint, the
TIC transcript must utilize a new TSS, in either the 5’ or
3’ gene, and we predicted the TSS in such cases based on
the longest open reading frame. In 22 of the 26 cases, the
new TSS site was in the 3
’ gene and preserved its reading
frame. Altogether, 155 TIC events (46%) preserved the
frame of the 3’ gene, which is somewhat higher than the
chance expectation of 33% and the finding of 36%
reported in a previous study [6].
In the 54% of cases where a frameshift occurred in the
3’ gene, we determined whether the CDS ended within
the last exon, because transcripts with a premature ter-
mination codon (PTC) should be degraded by the cellu-
lar nonsense-mediated decay (NMD) mechanism
[34,35]. We found a PTC in 167 (91%) of the 184 TIC
events with a frameshift in the 3’ gene. Overall, our ana-
lysis indicates that half of TIC events should be
degraded by NMD, and half should generate a protein
product.
We extended our analysis to predict the domains
encoded by the TIC protein products, and to compare
them with the original domains of the 5’ and 3’ genes.
We found that conservation of domains depended on
whether the reading frame was preserved (Figure 2F).
For TIC events with a full CDS from the original TSS of
the 5’ gene to the original stop codon of the 3’ gene,
domains should be lost only when the breakpoint occurs
b e f o r ea5 ’ domain or after a 3
’ domain. Among the 5’
genes that originally had an identifiable domain, all of
the domains were preserved in 70% of TIC events and
at least one was preserved in an additional 10%. For the
3’ genes, these values were 92% and 4%, respectively,
indicating that 3
’ domains are highly likely to be pre-
served in these TICs. Among the 86 TIC events with
identifiable domains in both the 5’ and 3’ genes, all
domains of both genes were preserved by the TIC pro-
tein in two-thirds (58) of cases.
For TIC proteins that had a 3’ frameshift or a new
TSS, but still had their terminating codon in the last
exon, domains were more likely to be lost. All
5’ domains were preserved in only 45% of cases, and all
3’ domains in only 44% of cases. TIC proteins with a
premature termination codon (PTC) have a frameshift
in the 3’ gene, and therefore preserve no 3’ domains.
Theoretically, the predicted effect on 5’ domains shows
that they should largely stay intact, with 78% of these
cases preserving all 5’ domains. However, since proteins
with a PTC are subject to degradation by NMD, they
should not produce a protein product.
Expression of TICs and their constituent genes
One advantage of RNA-Seq data is that it can provide
expression levels in addition to splicing information.
Although our targeted alignments are not useful for
determining expression, alignment of reads to either
known transcripts or the genome can provide expression
levels of genes or even exons. Our spliced alignment
method, described later, provided genomic alignments
for comparing the expression levels of 5’ and 3’ genes.
We used these alignments to compare the expression of
genes involved in observed TIC events with those not
involved. To remove possible confounding factors, we
required that the genes have an exon with a potential
TIC exon within 200,000 bp and that they be expressed
in the given sample, as determined by having an
observed intragenic splice in that sample. The results
(Figure 2G and 2H) indicate that 5’ and 3’ genes with
higher expression levels are more likely to give rise to
observable TIC events.
However, RNA-Seq is limited in its ability to measure
expression levels of rare splicing events, such as TICs. To
obtain expression levels of TIC splice events and to con-
firm our computational predictions, we performed
Nacu et al. BMC Medical Genomics 2011, 4:11
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Page 7 of 22experimental qRT-PCR assays of six TIC events from
among the 37 that had multiple supporting reads includ-
i n go n ef r o map r o s t a t et u m o rs a m p l e .R e g a r d l e s so f
which samples had an observed TIC splice, we evaluated
these TICs across our set of six prostate tumor and nor-
mal samples, as well as in a commercial sample of pooled
normal prostate RNA. In all cases, the TIC events were
detected in all samples (Figure 3A-F, left sets of barplots),
showing a ubiquitous expression pattern across prostate
tissues. However, we did see some variability in expres-
sion across our samples, especially for MSMB-NCOA4,
which was highest in the T2 and N2 samples; SLC45A3-
ELK4, which was highest in T3 and N3; and AZGP1-
GJC3, which were low in T2 and T3.
We also saw differences in the overall expression
levels across different TIC events, and the TIC events in
Figure 3A-F are arranged in increasing order of mea-
sured TIC splice expression. The two fusions with the
highest overall expression levels relative to GAPDH
were MSMB-NCOA4 and SLC45A3-ELK4, each showing
expression levels of up to 0.05 times the level of
GAPDH. The expression levels of the remaining fusions
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Figure 3 Expression of TICs and their component genes. (A-F) Each panel contains expression data for a TIC and its component genes, and
is labeled with the splice distance. The leftmost plot in each panel shows the expression of the TIC splice using qRT-PCR measurements relative
to GAPDH in prostate tumor samples T1-T3, matched normal prostate samples N1-N3, and a commercial sample of normal prostate (C). Error
bars indicate the standard error over 2 replicate measurements. The rightmost plots in each panel show expression of the 5
’ and 3
’ genes for the
T1-T3 and N1-N3 samples, as measured by RNA-Seq in reads per kilobase per million total reads (RPKM). TICs are presented from panel A to
panel F in order of increasing TIC splice expression. For panels A-C, expression of the 5
’ and 3
’ genes are plotted on the same scale. For panels
D-F, because expression of the 3
’ gene is extremely low relative to that of the 5
’ gene, expression of each 3
’ gene is plotted on its own scale.
Panel F for MSMB-NCOA4 has the greatest variance of expression values across samples and shows that TIC splice expression correlates with 5
’
gene expression, but not 3
’ gene expression. (G) Relationship between TIC and 5
’ gene expression, shown as a scatterplot. (H) TIC splicing
efficiency, computed as TIC splice expression divided by the 5’ gene expression, for each sample. In panels G and H, plot symbols A-F
correspond to the TICs labeled in panels A-F.
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Page 8 of 22tested were much lower, with ADCK4-NUMBL having
only 0.004, and HDAC8-CITED1 only 0.0009 the level
of GAPDH.
We used our RNA-Seq data to determine the expres-
sion of the 5’ and 3’ genes in each sample (Figure 3A-F,
right sets of barplots). In two of the TIC events (Figure
3A-B), the 5’ and 3’ gene expression levels are compar-
able, and in one TIC event, DUS4L-BCAP29 (Figure 3C),
the 3’ gene expression is higher than that of the 5’ gene
expression. However, in the remaining three TIC events
(Figure 3D-F), expression of the 5’ gene is several orders
of magnitude higher than that of the 3’ gene. When we
compare the expression pattern of the TIC splice with
that of its component genes, in most cases, we found a
general pattern of correlation between expression of the
TIC event and that of the 5’ gene, although there was
also some correlation with 3’ gene expression. These
results are generally consistent with other cases studied
in the literature, which have also shown correlations
between TIC expression and that of the 5’ and 3’ genes
[ 1 0 ] .H o w e v e r ,i no u rd a t a ,t h eT I Ce v e n tMSMB-
NCOA4, which had the greatest variance in expression
across samples showed consistency of TIC expression
with that of the 5’ but not the 3’ gene (Figure 3E).
We can compute the relationship between the TIC
splice expression with that of the 5’ gene, either as a
scatterplot (Figure 3G) or as a ratio (Figure 3H). This
relationship reflects the efficiency of TIC splicing rela-
tive to the amount of 5’ transcript available. Since the
data are plotted on a logarithmic scale, they suggest that
TIC splicing efficiency varies among different events by
several orders of magnitude, with the DUS4L-BCAP29
event having an efficiency 3000 times as high as that of
MSMB-NCOA4. TIC splicing efficiency does not appear
to be related to splicing distance, since we see much dif-
ferent levels for the two TIC events with the shortest
splicing distances of 4166 and 5955 nt.
Tissue specificity of TICs
Previous reports of the SLC45A3-ELK4 e4-e2 TIC have
found it to be specific to prostate cancer samples, parti-
cularly those that lack ERG expression [11]. We per-
formed a detailed study of this TIC by qRT-PCR in an
additional panel of 20 matched prostate tumor and nor-
mal samples (Figure 4A). Our assay detected at least
some level of TIC expression in all prostate samples but
none in any of 9 lung cancer cell lines, revealing that
expression is indeed tissue-specific. We also saw varia-
bility of TIC expression with extremely high levels in 2
of 7 ERG-negative tumors, at 0.35 and 0.11 times the
expression of GAPDH, and to a lesser degree, in their
matched normal samples. In the remaining 5 ERG-nega-
tive tumors, and in all 16 ERG-positive tumors, expres-
sion of the TIC was detectable, but at lower levels, and
with only three minor exceptions, expression of the TIC
was lower in cancer than in the matched normal sample.
Our data support earlier findings that low expression of
ERG appears to be a prerequisite, but not a sufficient
condition, for high cancer levels of the e4-e2 TIC event.
To explain the prostate-specific expression pattern of
the SLC45A3-ELK4 TIC, we examined expression data
from 2823 human normal and 1437 tumor samples
measured on the Affymetrix HG-U133 GeneChip, taken
from the GeneLogic (Gaithersburg, MD) database. We
found that the 5’ gene SLC45A3 is expressed specifically
in prostate tumor and normal samples (Figure 4B),
whereas the 3’ gene ELK4 is expressed broadly across
multiple tissues (Figure 4C). Therefore, the prostate-spe-
cific expression pattern of this TIC appears to be consis-
tent with expression of the 5’ gene.
We further compared the expression of SLC45A3 with
that of ERG in prostate samples (Figure 4D). The high-
est levels of expression of the 5’ gene are found in the
ERG-negative prostate tumor samples, although not in
all of them. Hence, we found further similarity of the
expression pattern of the TIC event and that of the 5’
gene relative to ERG expression, where low levels of
ERG expression appear to be a prerequisite, but not a
sufficient condition, for the highest levels of the 5’ gene
expression.
We also used the GeneLogic database to find other
examples of TIC events with prostate-specific expression
of the 5’ gene. We found such patterns for MSMB-
NCOA4, AZGP1-GJC3, ENTPD5-FAM161B, TMC5-
CP110, TPD52-MRPS28, IVD-BAHD1,a n dKLK11-
KLK7. Among these gene pairs, the read evidence was
strongest for MSMB-NCOA4 (8 reads over two iso-
forms) and AZGP1-GJC3 (41 reads), with only 1 or
reads for each of the other gene pairs.
MSMB (Figure 5A) shows high expression in normal
stomach and lung cancer samples, in addition to pros-
tate samples, and appears to show higher expression in
prostate normal samples than in prostate cancer sam-
ples. The expression of AZGP1 (Figure 5C) is high in
breast, head and neck, and liver samples in addition to
prostate. For both of these 5’ genes, their corresponding
3’ genes (Figure 5B and 5D) do not show evidence of
prostate specificity.
The prostate specificity of our supporting reads was
consistent with the microarray-based prostate specificity
of the 5’ genes. For example, the MSMB-NCOA4 event
was supported by 3 prostate tumor reads and 2 normal
reads for the e3-e2 isoform, and by 1 tumor and 2 nor-
mal reads for the e2-e2 isoform, and was not observed
in the HBR or UHR samples. Likewise, the AZGP1-
GJC3 profile was supported by 7 reads across all three
prostate tumor samples, and by 33 reads across all three
normal prostate samples; it was also supported by one
Nacu et al. BMC Medical Genomics 2011, 4:11
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Page 9 of 22read from the HBR sample. The TIC events with pros-
tate-specific 5’ genes each had TIC support from one or
two prostate samples, without any reads from HBR or
UHR.
To survey the extent of tissue specificity in all of our
observed TIC events, we constructed a heatmap to show
the mean expression of the 5’ gene across a panel of
normal tissues (Figure 6). This heatmap shows that 5’
genes have a varying degrees of tissue specificity.
Although it is difficult to define tissue specificity pre-
cisely, approximately half of the genes, in the bottom
part of the heatmap, are strongly specific to one organ,
with many expressed specifically in either leukocytes or
in the brain. An additional one-fourth show weaker
levels of tissue specificity, and one-fourth have relatively
uniform expression over all tissues. The implication of
these findings for the tissue specificity of TIC expression
depends on the dependence of TIC expression on that
of the 5’ gene.
Spliced alignment method
We also explored an alternative, spliced alignment strat-
egy for finding TICs by identifying splicing events within
individual reads using our GSNAP program [27]. Our
program provides options for finding splicing based on
a probabilistic splice site model or a user-provided data-
base of known splice sites. We used both sources of
evidence in our alignments to the human genome,
w i t ht h es a m es e to fs p l i c es i t e sb a s e do nR e f S e qt r a n -
scripts as we used for the targeted alignment method.
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Figure 4 Expression patterns of the SLC45A3-ELK4 e4-e2 TIC and related genes. (A) qRT-PCR levels of SLC45A3-ELK4 e4-e2 TIC in the
sequenced prostate tumor and normal sample pairs T1/N1, T2/N2, and T3/N3 pairs (labeled as 1-3, and marked with “-” for ERG-negative and “+”
for ERG-positive status), plus panels of 6 ERG-negative and 14 ERG-positive prostate tumor and normal matched samples, a commercial sample of
prostate normal RNA, and 9 lung cancer cell lines. (B) Microarray-based expression profile of SLC45A3 (Affymetrix probe 228696-at on GeneChip
HG-U133B) across human tissues, showing prostate specificity. Samples are organized by tissue, with normal samples above (green) and cancer
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200,000 bp should therefore yield a subset of the results
found in the targeted alignment approach. This method
should be less sensitive than targeted alignment, because
the version of GSNAP we used requires 14 nt on each
side of an exon-exon junction to identify a spliced align-
ment, rather than the 8 nt we used for targeted align-
ment. (More recent versions of GSNAP can detect short
overhangs when a database of known splice sites is
provided.)
For the resulting spliced alignments, we applied the
same clustering and filtering steps as for the targeted
alignment approach, and found over two-thirds (231) of
the 339 TIC events that were found by targeted alignment.
These events were based upon 427 TIC alignments, which
is half of the number found with targeted alignment. How-
ever, the sensitivity rate depended heavily on read length.
For samples sequenced at 33-nt, spliced alignment yielded
only 24 TIC alignments, which is only 18% of those found
with targeted alignment. For samples sequenced at 50-nt
or more, spliced alignment yielded 59% of the TIC align-
ments found by targeted alignment.
Transcription-induced chimeras with intervening exons
Although spliced alignment is less sensitive than tar-
geted alignment, it does have the ability to find novel
splicing at locations not included in a database of
known splice sites. We observed many novel splice sites
occurring within genes, corresponding to cryptic splice
sites or novel exons. However, we were especially
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Figure 5 Expression profiles for 5’ and 3’ genes in prostate-specific TICs. Expression profiles for (A) MSMB,( B )NCOA4,( C )AZGP1, and (D)
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Figure 6 Tissue specificity of 5’ genes in observed TICs. Heatmap of gene expression across a panel of normal tissues for the 5’ genes
corresponding to all observed TICs. Data are taken from the GeneLogic (Gaithersburg, MD) database. Each bar in the heatmap represents the
mean expression of the 5’ gene in the given tissue. Expression is scaled within each gene to have uniform standard deviation over all genes,
and then plotted using its logarithmic value, further transformed by the normal distribution function to achieve a bounded range of colors.
Gene expression level is indicated by color, with red indicating increased expression, and green indicating decreased expression.
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Page 12 of 22interested in novel exons in the context of TIC events.
A previous study [5] found several cases where EST
clusters revealed a novel exon between two genes in a
TIC, accounting for 12% of the gene pairs in their study.
Such transcription-induced chimeras with intervening
e x o n s ,w h i c hw ec a l lT I C I E s ,a r em o r ec h a l l e n g i n gt o
find using RNA-Seq 33- to 50-nt short reads, because
they are generally not long enough to span the two
introns surrounding most exons. However, we can
detect parts of a TICIE by finding novel splicing events
on both ends of an apparent intervening exon.
To identify such events, we looked for spliced align-
ments of 200,000 bp or less involving one known site
from the database and one novel site based on a prob-
abilistic splice model as implemented in GSNAP. For
each sample, we recorded pairs where the novel splice
sites were within 300 bp of each other, which was our
threshold for exon length. For the T1, T2, T3, and N3
samples with 33-nt reads, we found 22, 39, 70, and
40 novel exons, respectively. For the N1, N2, HBR, and
UHR samples with longer reads, we found 1315, 753,
1427, and 1502 novel exons, respectively. Novel splicing
is reported by GSNAP more frequently with longer read
lengths, because the program uses a sliding scale of
alignment length and probabilistic model score to help
find true positive novel splicing events.
The vast majority of these novel exons represent intra-
genic cases where both known splice sites belonged to
the same gene. To find TICIE events, we extracted
novel exons where the known splice sites were on differ-
ent genes and further applied our homology filtering
step described previously to eliminate probable false
positive events. We further considered only cases where
the known genes were coding and well annotated, as
indicated by a RefSeq accession prefix of “NM_”.
We found 30 TIC events having an intervening exon,
with 22 (73%) having their intervening exon occurring
between the (n - 1) exon and +2 exon (Additional file 3).
Therefore, the (n - 1) to +2 exon pattern was stronger in
TICIE events than in TICs, where only 51% had this pat-
tern. In half (14) of the cases, the intervening exon was
located in the intergenic region, distinct from exons of
the original genes; in 7 cases, it overlapped the last exon
of the 5’ gene; and in 8 cases, it overlapped the first exon
of the 3’ gene. In the remaining case, EIF3K-ACTN4 e4/
8-e2/21, the intervening exon was a novel exon between
e4 and e5 of the 5’ gene.
These TICIE events involved 26 distinct gene pairs,
because four gene pairs had a second isoform. Three of
t h e s ei s o f o r m si n v o l v e da na l t e r n a t es p l i c es i t ei nt h e
intervening exon, (e.g., Figure 1B), while the remaining
isoform involved an alternate splice site in the upstream
gene (Figure 1C). For 6 of the gene pairs, our previous
targeted alignment analysis had also found a direct TIC
event without an intervening exon between the 5’ and 3’
gene pairs. One example, VAMP8-VAMP5 (Figure 1B),
shows that the direct TIC and multiple TICIE isoforms
can be found in the same sample N1.
We measured the coding potential of the TICIE events
both with and without the intervening exon, and com-
pared each with the original genes. Without the inter-
vening exon, 10 events would give a full CDS, 14 started
from the original TSS but had a frameshift of the 3’
gene, and 6 had a new TSS. With the intervening exon,
these counts changed to 5, 19, and 6, respectively.
Therefore, intervening exons generally had a detrimental
effect on the coding potential, relative to the original
frames. The lack of preference for coding potential was
also supported by the fact that intervening exons had
lengths that were a multiple of 3 in 12 cases, approxi-
m a t e l yt h es a m ea st h e1 0t h a tw o u l db ee x p e c t e db y
random chance. The 18 intervening exons with lengths
that were not multiples of 3 caused the 3’ gene to go
out of frame in 4 cases; go into frame in 2 cases; change
one premature stop codon to a different premature stop
codon in 8 cases; and had no effect in 4 cases because
the new TSS occurred after the intervening exon. The
intervening exons caused loss of domains in 6 cases
relative to the TIC if it had lacked the intervening exon,
and a gain of domains in one case by restoring the
frame of the 3’ gene. We checked to see if any interven-
ing exons introduced a new domain into the protein,
but did not find any such cases.
We found that EST-genomic alignments supported
t h r e e - f o u r t h so fo u rT I C I Es p l i c i n ge v e n t s :3o ft h e3 0
events had EST support for their upstream-to-interven-
ing splices only; 11 had EST support for their interven-
ing-to-downstream splices only; and 9 had EST support
for both splices. Among the 9 TICIE events with EST
support for both splices, 4 had at least one EST that
spanned both the upstream-to-intervening and interven-
ing-to-downstream splices (including the two events in
Figure 1C).
We compared our TICIE gene pairs with those found
by Akiva and colleagues in their study, and found five in
common, although in three cases, the previous study
found TIC events for the gene pair rather than our
TICIE events. In one case, ZNF763-CHST7,o u ri n t e r -
genic exon was identical to that found previously
(although the upstream splice site was different), and in
the other case, VAMP8-VAMP5,w ef o u n dt w oi n t e r -
genic exons that were different from that found
previously, with all three exons sharing the same 3’ end
and having different 5’ ends (Figure 1B).
Distant fusions
Another advantage of the spliced alignment approach is
its ability to detect long-range intrachromosomal fusions
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tion of translocations in RNA-Seq data is not novel, our
s i n g l e - e n ds h o r tr e a d sa r en o ta si d e a lf o rt h i sp u r p o s e
as paired-end or longer reads of 100-200 nt [11]. Never-
theless, our results based on GSNAP on short reads are
noteworthy for comparison with previous studies, espe-
c i a l l yt h o s ea n a l y z i n gt h es a m eH B Ra n dU H Rs a m p l e s
[17]. In addition, our analysis of distant fusions provides
a contrast with our analysis of TIC events, even though
both are supported by the spliced alignment approach.
Our genomic alignments gave a total of 29 long-range
intrachromosomal fusion candidates of greater than
200,000 bp; 36 scrambled candidates in which the
acceptor splice site was upstream of the donor splice
site; 59 inversion candidates with the splice sites on
opposite strands of the same chromosome; and 223
interchromosomal candidates, or translocations (Addi-
tional files 4 and 5).
Almost all of these fusions were identified through the
50-nt reads from N1, N2, HBR, and UHR. Filtering
steps are also necessary to eliminate false positives from
among these candidates, due to various causes, including
library artifacts. Since most of our candidates were sup-
ported by a single read, one simple filtering criterion
was to consider only fusions supported by multiple
reads, of which we found 19 (Table 2).
In contrast with TIC events, which often had read
support from multiple samples, distant gene fusions
were each found in only a single sample, with the excep-
tion of TMPRSS2-ERG, which was found in T2, T3, and
N3 (although the N3 had only a single read which may
be due to contamination with adjacent tumor tissue).
Also, whereas we found many cases of multiple isoforms
for TIC events, such isoforms were rare for distant
fusions, with the exception of the RPS6KB1-TMEM49
scramble, where we found two isoforms, e2-e12 and
e4-e12, in the UHR sample. We cannot determine from
the transcriptional sequence data if these isoforms
are present at the genomic DNA level, or are due to
alternative splicing. However, numerous isoforms have
been found for the TMPRSS2-ERG fusion junction,
including multiple isoforms in the same sample, suggest-
ing that they are due to alternative splicing occurring
after a single genomic event [36].
We also found that spliced alignment using even 50-nt
reads can be challenging, as demonstrated by our align-
ment of the BCAS4-BCAS3 fusion. We found this fusion
only because GSNAP provides SNP-tolerant alignment,
Table 2 Distant gene fusions with multiple read support
Samples Donor Gene (RefSeq) Exon 5’ chr 3’ chr Acceptor Gene (RefSeq) Exon Distance Notes
Long distance
HBR(2) IQCJ (NM_001042705) 4/5 +3 +3 SCHIP1 (NM_014575) 2/8 501759 5
N3(1), T2(5), T3(15) TMPRSS2 (NM_005656) 1/14 -21 -21 ERG (NM_004449) 4/11 3062463 7
Scrambled exons
UHR(2) RPS6KB1 (NM_003161) 4/15 +17 +17 TMEM49 (NM_030938) 12/12 74936 3,6
UHR(2) GCN1L1 (NM_006836) 2/58 -12 -12 MSI1 (NM_002442) 12/15 157217
Inversions
UHR(7) GAS6 (NM_000820) 12/15 +13 -13 RASA3 (NM_007368) 23/24 185397 6
UHR(2) TGOLN2 (NM_006464) 3/4 -2 +2 USP39 (NM_006590) 11/13 320033
UHR(4) ARFGEF2 (NM_006420) 1/39 +20 -20 SULF2 (NM_018837) 3/21 1172861 2,4,6
UHR(2) LITAF (NM_001136472) 1/4 -16 +16 DECR2 (NM_020664) 2/9 11193286
N1(2) REV1 (NM_016316) 3/23 -2 +2 CPSF3 (NM_016207) 10/18 89944295
Translocations
UHR(4) BCAS4 (NM_017843) 1/6 +20 +17 BCAS3 (NM_017679) 23/24 3,4,6
UHR(3) BCR (NM_004327) 14/23 +22 +9 ABL1 (NM_005157) 2/11 1,6
N1(2) CAMTA1 (NM_015215) 3/23 +1 -12 SPPL3 (NM_139015) 3/11
UHR(2) DYNC1H1 (NM_001376) 24/78 +14 +12 EIF4B (NM_001417) 8/15
T3(2) MBTPS1 (NM_003791) 22/23 -16 +15 SERF2 (NM_001018108) 3/3
N2(2) OGT (NM_181672) 6/22 +X -5 RBM22 (NM_018047) 4/11
N1(2) ROR2 (NM_004560) 1/9 -9 -17 USP36 (NM_025090) 2/20
T3(2) SEC31A (NM_014933) 1/27 -4 -6 C6orf62 (NM_030939) 2/5 7
UHR(2) TIMM9 (NM_012460) 3/6 -14 -8 PRKDC (NM_006904) 26/86
N1(2) ZDHHC8 (NM_013373) 4/11 +22 +19 UBL5 (NM_024292) 3/5
Each sample shows the number of supporting reads for the given fusion in parentheses. Exon values refer to the exon number and total number of exons in the
given RefSeq transcript. Notes: (1) Known fusion in chronic myelogenous leukemia. (2) Observed in [53]. (3) Observed in [54]. (4) Observed in [55]. (5) Observed
in [38]. (6) Observed in [17]. (7) Confirmed by PCR in this study.
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G allele occurs at SNP rs2272962 in BCAS4 13 nt
upstream of the exon-exon junction. Without our SNP-
tolerance feature, this SNP would preclude a consecutive
14-nt stretch of upstream matches needed by GSNAP
for genomic localization. Alternatively, we could also
have avoided this difficulty with longer read lengths that
would have given sufficient sequence specificity to toler-
ate a SNP near the fusion junction.
As shown in Table 2, many of our distant gene fusions
have confirmatory evidence from the literature, espe-
cially in the MCF7 breast cancer cell line. The presence
of cell line fusions in UHR can be explained by its deri-
vation from 10 cancer cell lines, originating from breast
adenocarcinoma, cervical adenocarcinoma, glioblastoma
multiforme, melanoma, hepatoblastoma, embryonal car-
cinoma, liposarcoma, Hodgkin’s lymphoma, plasmacy-
toma and T-cell lymphoblastic leukemia [37]. One long-
distance fusion, IQCJ-SCHIP1, found in HBR and span-
ning 501,759 bp, has been found previously to be highly
expressed in the brain [38]. There are no other RefSeq
transcripts between these two genes and the fusion pat-
tern fits the characteristic (n -1 )t o+ 2p a t t e r n ,s ot h i s
fusion may possibly represent an unusually long TIC.
Our method identified five of the seven most prevalent
fusions in UHR as reported by a method using paired-
end reads [17]. In addition, we also observed the
NUP214-XKR3 fusion reported in that paper, but had
only a single read supporting that fusion.
In contrast, the only distant gene fusions with evi-
dence from 33-nt reads were two long-range interchro-
mosomal fusions (C16orf58-NUPR1 and TMPRSS2-ERG
e1-e4), three apparent inversions, and 14 apparent
translocations. Among these putative fusions, the only
ones with multiple supporting reads were TMPRSS2-
ERG (with 5 reads from T2, 15 from T3, and 1 from
N3) and the translocations MBPTS1-SERF2 and
SEC31A-C6orf62 (each with 2 reads from T3).
The TMPRSS2-ERG fusion is known to be prevalent
in prostate cancer, with the predominant isoform being
e1-e4 [31,39], which we found in our reads. The second
most common isoform is e1-e5 [36], which we did not
find in our reads. However, we performed quantification
of both isoforms in our samples by qRT-PCR, and found
that both isoforms were present in T2 and T3 and at low
levels in N2 and N3 (Figure 7A), with the e1-e5 isoform
being present at one-tenth the level of the e1-e4 isoform.
Since the TMPRSS2-ERG fusion is known have a genomic
origin, due either to a translocation or to a 3-million-bp
genomic deletion between the genes [40], the presence of
both isoforms in the same sample can be explained either
by tumor heterogeneity or by alternative splicing. We per-
formed comparative genomic hybridization (CGH) micro-
array analyses of our samples, and found the deletion to
be visibly evident in T3 but not in T2 (Figure 7D), indicat-
ing that T2 is of the translocation type.
We further tested for the presence of the other candi-
date long-range interchromosomal fusion C16orf58-
NUPR1 i no u rp r o s t a t es a m p l e sb u tf a i l e dt of i n di tb y
qRT-PCR, suggesting that spliced alignment of 33-nt
reads can give false positives in distant fusions. On the
other hand, we also tested for the translocation
SEC31A-C6orf62 e1-e2, and confirmed its presence in
the T3 sample, but not in other samples (Figure 7B).
Although the version of GSNAP we used requires at
least 14-nt on each side of the exon-exon junction to to
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Figure 7 Distant fusions. (A) Expression level of TMPRSS2-ERG e1-e4 and e1-e5 fusion splices in prostate tumor and normal samples measured
by qRT-PCR, compared with ERG expression as measured by RNA-Seq. qRT-PCR measurements are shown for prostate tumor samples T1-T3,
matched normal prostate samples N1-N3, and a commercial sample of normal prostate. RNA-Seq measurements are shown fir T1-T3 and N1-N3.
(B) Comparison of SEC31A-C6orf62 expression level with downstream C6orf62 expression. Fusion is observed only in the T3 sample. (C)
Comparison of IRS2-NUFIP1 expression level with downstream NUFIP1 expression. Fusion is observed only in the T2 sample. (D) CGH microarray
data for chromosome 21, containing the TMPRSS2-ERG fusion. A corresponding genomic deletion is observed in the T3 sample, but not in T2,
indicating that the gene fusion in T2 is due to translocation. (E) CGH microarray data for chromosome 13, containing the IRS2-NUFIP1 fusion. No
corresponding genomic deletions are observed.
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Page 15 of 22report a candidate gene fusion, we relaxed this criterion
to see if we could identify other distant fusion events,
and obtained the candidate long-range intrachromoso-
mal gene fusions KRT24-NCOR1, LIN37-GPSN2,a n d
IRS2-NUFIP1. We tested each of these candidates by
qRT-PCR, but found confirmation only for IRS2-
NUFIP1 e1-e8 in T2 (Figure 7C). This fusion spans 64
million bp on chromosome 13. However, our CGH
microarray data showed no evidence of a genomic dele-
tion (Figure 7E), suggesting translocation as the prob-
able mechanism.
To evaluate the generalizability of the two novel dis-
tant gene fusions that we verified experimentally, we
tested for the presence of both SEC31A-C6orf62 and
IRS2-NUFIP1 by qRT-PCR in an additional 51 primary
prostate tumor samples, but were unable to detect these
fusions in any of these other samples, indicating that
they are private fusion events. In addition, when we
examined the expression of the downstream genes using
our RNA-Seq data, we found no evidence that these
fusion events increase the expression of the 3’ gene
(Figure 7B and 7C). This is in contrast with TMPRSS2-
ERG, where presence of the fusion greatly increases
expression of the downstream gene (Figure 7A).
Functional analysis of IRS2-NUFIP1 s h o w st h a ti th a s
an in-frame coding region starting from the original
TSS of IRS2 and maintaining the frame of NUFIP1.I t
retains the IRS and PH domains of IRS2, but because
the breakpoint occurs after the NUFIP1 domain of
NUFIP1, it loses that domain and presumably function-
ality of the 3
’ gene. For the SEC31A-C6orf62 fusion, the
breakpoint occurs before the TSS of SEC31A. The long-
est open reading frame of the gene fusion gives a
peptide that consists of the 171 amino acids on the
C-terminal of the original 229-aa protein for C6orf62.
No domains in the Pfam database were found for either
SEC31A or C6orf62.
Discussion
Our ability to identify TIC events with high sensitivity
using short reads highlights the utility of a targeted
alignment approach in dealing with RNA-Seq data. Pre-
vious analyses of transcriptional data have reported rela-
tively few TIC events, despite their use of longer or
paired-end reads. In contrast, the 339 distinct TIC
events found in our study greatly expands the known
universe for this phenomenon. Combined with the EST-
based surveys, these events contribute towards a total of
at least 567 gene pairs with observed TIC events so far.
These gene pairs comprise twice as many genes, already
within the previous estimates that 4-6% of genes in the
g e n o m ea r ei n v o l v e di nT I Cf o r m a t i o n[ 6 ] .G i v e nt h e
low degree of overlap among the two EST-based studies
and our RNA-Seq study, we would expect that future
RNA-Seq studies should contribute even more new TIC
events, suggesting that 4-6% involvement is an underes-
timate. Rather, our study is in line with the RACE-based
finding that perhaps one-third of genes have a TIC
event in some tissue [14].
Our study has identified a wider range of distinct TIC
events than have been found in other RNA-Seq studies
to date, even those that have focused on finding gene
fusion events. We believe that there are two major rea-
sons for this disparity. First, previous RNA-Seq studies
have looked at the more general problem of finding
gene fusions, rather than having a specific procedure for
finding TICs. The general approach to identifying gene
f u s i o n si n v o l v e sa ni n i t i a lstep to identify candidate
fusion gene pairs based on discordant mappings
between the ends of paired-end reads, and then a sec-
ond step to align reads to exon-exon junctions between
the candidate gene pairs. However, the initial step may
miss gene pair candidates since it requires sufficient evi-
dence from paired-end reads for their consideration. In
contrast, our TIC-specific analysis begins with the entire
set of possible sufficiently close and adjacent gene pairs
in the genome as candidates, which provides greater
sensitivity for finding TICs. In addition, filtering proce-
dures that are designed to limit false positives for the
general class of gene fusions may be more stringent
than those needed to identify TICs specifically.
A second reason for the disparity is that TIC events
appear to occur at relatively low levels across the gen-
ome. Using our criterion of requiring an 11-nt overhang
over the exon-exon junction, we found that TIC events
represented only 1 per 40,000-120,000 reads, and these
were spread over the hundreds of different gene pairs
having a TIC event. Therefore, bioinformatics methods
that use frequency as a criterion may miss such TIC
events. For example, the FusionSeq algorithm [19] relies
upon a metric called SPER that represents the number
of supporting reads per million mapped reads. A fre-
quency-based criterion such as this may miss phenom-
ena such as TICs that occur at low levels, and will be
biased toward TICs that have high levels of expression.
Likewise, the analysis by Maher and colleagues [11]
ranked their candidates by the total number of mate
pairs or long reads that spanned the fusion junction per
million mapped reads.
We believe that a probabilistic approach may ulti-
mately be more useful than a simple frequency-based or
counting approach. If a plausible biological mechanism
exists for TIC formation, then TIC events should be
given a higher prior probability, so that less read evi-
dence is necessary for making an inference about the
presence of a TIC event. In addition, in a probabilistic
analysis, spliced alignments across TIC gene pairs
should provide higher odds ratios than alignments
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tance of TIC gene pairs in the genome limits the uni-
verse of possible alternative hypotheses. These
probabilistic ideas are embodied in our own analysis
where, for example, we accepted TIC candidates based
on a single read, but required multiple reads before con-
sidering a gene fusion candidate. It is possible, though,
that our 212 single-read candidates are less likely to be
true positives, since only 28% of them had external sup-
porting evidence, whereas 54% of our 127 multiple-read
candidates did so. Alternatively, the single-read candi-
dates may represent TICs that are expressed at lower
levels and therefore less likely to have been found by
EST-based approaches.
Nevertheless, our computational estimate of the false
discovery rate for our pipeline is 1.5%, suggesting that
98% of our TIC events represent true biological events.
Our experimental validation rate of 6 out of 6 is consis-
tent with a recent study of gene fusions in prostate can-
cer [18], in which 9 of the 11 predicted readthrough
fusions were experimentally validated. In addition, the
predominance of short splicing distances and the (n -1 )
to +2 pattern in our data would not occur if our fusion
events were due to library artifact or spurious align-
ments. It is also unlikely that sequencing errors, which
typically give mismatches or indels, could artefactually
generate nucleotide sequences from disparate exons.
However, our study also highlights some of the limita-
tions of a targeted alignment strategy, especially its
inability to be used generally to find gene fusion events.
In our process of constructing exon-exon targets, we
found approximately 180,000 unique donor sites and
180,000 unique acceptor sites in the human genome. To
represent all exon-exon pairs would require 32 billion
exon-exon targets, and for targets each of length 150 nt,
we would have a need to index 5 trillion nucleotides, a
value that exceeds the limits of GSNAP, for example, by
a factor of 1000. What makes targeted alignment feasi-
b l ef o rt h eu n i v e r s eo fT I C si st h ec o n s t r a i n tt h a tt h e
splice sites lie within 200,000 bp, which limits the num-
ber of exon-exon junctions to 2.5 million, a small frac-
tion of the total set of possibilities. Nevertheless,
targeted alignment can still be used as a sensitive
method for finding preselected gene fusion events. In
fact, an analogous experimental strategy using microar-
rays has been developed where all combinations of
exon-exon junctions between selected pairs of fusion
genes are represented by oligonucleotide probes [41].
However, our study also shows that as read lengths
become longer, a spliced alignment approach is also
effective in identifying most of the TIC events found by
the targeted alignment approach.
Another limitation of targeted alignment in this study
is that we restricted our analysis to readthrough fusions
across adjacent genes on the same genomic strand. Our
analysis therefore excludes gene pairs in the same geno-
mic region but on opposite strands, which have been
called converging or diverging fusions [11] or cis-type
fusions [18,19]. Our analysis also excludes fusions
between nearby genes that skip across an intervening
gene. Nevertheless, a targeted alignment strategy could
be readily extended to handle these types of events.
In contrast with these other local fusion types and
more distant gene fusions, which generally have a DNA-
based mechanism, readthrough fusions have a plausible
RNA-based mechanism. In particular, the biological
mechanism supported by our study and by previous stu-
dies is that TICs are largely a “leakage” or cis-based
event. Although TICs could potentially be caused by a
trans-splicing mechanism between two different tran-
scripts, the proximity of the gene pairs makes a cis
mechanism involving a single transcript more plausible.
A cis-based mechanism is also supported by our identifi-
cation of 30 TICIE events, since intergenic exons are
unlikely to be incorporated by a trans-splicing mechan-
ism between two separate gene transcripts.
Under a leakage mechanism, the first step to generat-
ing a TIC involves a failure to terminate transcription of
the 5’ gene. Such a mechanism is suggested by previous
findings [11] that TICs have a broad pattern of expres-
sion across multiple samples, in contrast with other
types of gene fusions that tend to have a restricted pat-
tern of expression in particular samples. Further support
is provided by this study which indicates that TICs are
be found more readily when the upstream gene is
expressed at higher levels, and that expression levels of
TICs correlate with those of the 5’ gene, although we
often observe some association with 3’ gene expression
as well.
A tissue-specific pattern of the 5’ gene can therefore
give rise to tissue-specific expression of TICs. For exam-
ple, for the TICs MSMB-NCOA4 and AZGP1-GJC3,o u r
read evidence is restricted to prostate samples, which
corresponds to the prostate-specific expression pattern
of the 5’ gene and not the 3’ g e n e .F u r t h e r m o r e ,w e
can explain the prostate-specific and ERG-negative
expression pattern of the SLC45A3-ELK4 fusion based
on expression of the 5’ gene SLC45A3. Similarly, pre-
vious researchers observed the HHLA1-OC1 fusion in
those teratocarcinoma cell lines where HHLA1 was
expressed highly [7].
However, we cannot rule out the possibility that other
factors may increase or decrease the expression of parti-
cular TIC events. In our study, we found widely
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expression of the 5’ gene. Evidence from other research-
e r ss u g g e s t st h a te x p r e s s i o no fT I C sm a yb ei n c r e a s e d
by cellular stimuli, as has been shown for the SLC45A3-
ELK4 e1-e2 fusion [12] and for trans-splicing products
[32]. It is also possible that genomic deletions or other
alterations in intergenic regions may remove or alter
signals for transcriptional termination, making TIC
events more likely to occur in some samples.
The second step in a leakage mechanism should
involve splicing between the two genes on the same
transcript. As with typical splicing, such splicing would
be opportunistic, tending to occur between the closest
pair of splice sites at the shortest possible distance,
which we also observe. However, alternate splicing
could still occur between genes, and such alternate
choices presumably explain our finding of several cases
of gene pairs having multiple TIC isoforms. The fact
that TICs conserve the +2 splice site more strongly than
the (n - 1) splice site could be explained by the more
discriminating signals that surround acceptor sites,
including the polypyrimidine tract and the lariat signal.
In contrast with the large number of TICs found in
this study, we found relatively few distant gene fusions,
and experimentally verified only two novel ones in pros-
tate adenocarcinoma: IRS2-NUFIP1 and SEC31A-
C6orf62. One reason for this is that our data consisted
of short 33-bp single-end reads, whereas paired-end
data are more sensitive for finding distant gene fusions
[17]. Another reason may simply be the relative infre-
quency of gene fusion events in prostate cancer; a recent
RNA-Seq study [18] of 25 prostate cancers (7 ETS-posi-
tive and 18 ETS-negative) using paired-end 50-mers
yielded only 7 verifiable gene fusions. Interestingly, in
that study, the 5 gene fusions that did not involve an
ETS-family gene were all found in ETS-positive samples.
Likewise, the two gene fusions found in our study were
also found in ETS-positive samples, consistent with the
hypothesis that TMPRSS2-ERG rearrangements may
correlate with other rearrangements, possibly induced
by a common predisposing mechanism such as binding
by androgen receptor to the genome [42].
The functional role, if any, of TICs remains an open
question. Our study suggests that half of TICs terminate
in their last exon, therefore avoiding degradation by
nonsense-mediated decay, and among these proteins,
domains should largely stay intact. Our computational
analysis is subject to some caveats, however. Alternate
polyadenylation sites can result in a last exon different
from the one we have predicted, and alternate transcrip-
tion start sites can mean that the actual coding region is
different from the one predicted. Experimental evidence
to determine the precise peptides encoded by TICs may
require high-throughput proteomic analyses [43]. In
addition, we should note that the loss of a domain in a
TIC does not necessarily imply decreased gene function,
since a loss of negative regulatory region can result in
increased function of a gene.
Accordingly, it appears that transcription-induced chi-
meras, like gene fusions and other splicing anomalies
[44], may play a role in cancer. Examination of the TIC
events in our study reveals several that involve cancer-
associated genes, including the oncogenes E2F1, MAFG,
MRAS, NTRK1,a n dRHOC.O n eT I Cd i s c o v e r e di no u r
study with particular relevance to prostate cancer is
MSMB-NCOA4, for which we found two isoforms,
e3-e2 and e2-e2, with the latter isoform supported by
three ESTs. Both of these isoforms fit the (n -1 )t o+ 2
pattern, since the MSMB g e n eh a sa l t e r n a t ef o r m sw i t h
two or three exons. Analysis of the e3-e2 fusion suggests
t h a ti tm a yb es u b j e c tt oN M D ,b u tt h ee 2 - e 2f u s i o n
should maintain the frame of the 3’ gene and preserve
the 5’ and 3’ domains. The upstream partner, microse-
minoprotein beta, codes for a constituent of semen and
has been shown in two genome-wide association studies
[45,46] to be linked to prostate cancer risk. The down-
stream partner, also known as ARA70 (androgen recep-
tor associated protein 70), is also potentially relevant to
prostate cancer, since it is known to enhance the tran-
scriptional activity of androgen receptor in prostate
cancer cells [47]. Taken together, the high expression of
the upstream gene in prostate tissue, combined with the
physiological relevance of the downstream gene, sug-
gests a possible role for this TIC in prostate cancer
biology.
However, we should note that many TICs, and indeed
many gene fusions, may not have a functional role at all.
T h e ym a yb ep r i v a t eo rp a s s e n g e re v e n t s ,m u c hl i k e
those found in surveys of point mutations in cancer
[48]. The novel distant gene fusions found in this study,
IRS2-NUFIP1 and SEC31A-C6orf62, appear to fall into
this category. We found these fusions to present in
tumor samples and not in their matched normal sam-
ples, confirming that they were somatic in origin, but
each fusion occurred only once among 54 prostate
tumor samples tested. In addition, among the 7 prostate
cancer gene fusions found in the FusionSeq-based study
[18], only two had a duplicate occurrence among the
200 additional prostate tumor samples they tested.
Nevertheless, even driver gene fusions may be rare, as in
the case of R3HDM2-NFE2, which was found in only 2
of 76 lung adenocarcinoma samples [49]. Therefore,
additional work may be necessary to further characterize
the function of candidate fusion events or the TIC
events found in our study. Nevertheless, deep transcrip-
tional sequencing remains an important approach for
identifying novel phenomena that can serve as candi-
dates for further investigation.
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A targeted alignment approach provides a sensitive
method for identifying TICs in short read data, while
spliced alignment reveals numerous cases of intervening
exons between adjacent genes as well as gene fusions.
Both methods applied to deep transcriptional sequen-
cing data demonstrate a large number and diverse range
of TIC events within individual tissues. The low degree
of overlap among the two EST-based studies and our
RNA-Seq study suggest that TIC events are widespread
and that previous estimates of 4-6% genes involved in
TICs are an underestimate. Combined evidence from
RNA-Seq-based expression and qRT-PCR measurements
support a cis-splicing mechanism, in which the tissue
and cancer specificity of TIC events are controlled by
expression patterns of the upstream gene.
Methods
Samples
Samples used in this study are listed in Additional file 6.
All of the prostate samples in our study were reviewed
by Board-certified pathologists at our institution. Three
human primary prostate tumors (T1, T2, and T3) and
adjacent matched normal tissue samples (N1, N2, and
N3) were obtained from commercial sources with
appropriate consent and institutional approval. Pathol-
ogy review showed that the tumor samples had a tumor
content of at least 70%.
The human brain reference (HBR) RNA sample was
obtained from Ambion catalog number 6050. The uni-
versal human reference (UHR) samples was obtained
from Stratagene catalog number 740000.
Normal human prostate control (C) total RNA was
obtained from Clontech (Mountain View, CA), catalog
number 636550, and used in TaqMan verification.
The SLC45A3-ELK4 fusion was evaluated in an addi-
tional panel of 20 prostate tumors and their matched
normals, as well as 9 lung cancer cell lines: DMS79,
H23, H522, H1703, H520, H1838, H1563, H1688, and
H1734. The IRS2-NUFIP1 and SEC31A-C6orf62 fusions
were tested in an additional 51 prostate tumors, as
shown in Additional file 6.
Transcriptional sequencing
RNA and DNA were extracted using the Qiagen AllPrep
RNA/DNA kit. Libraries used in sequencing were con-
structed by random priming with polyA. Messenger
RNA was isolated from total RNA by poly-dT capture
and enrichment. Adapters for sequencing were ligated
to the cDNA per manufacturer’s instructions (Illumina,
Hayward, CA). The processed libraries were sequenced
by Illumina on a Genome Analyzer using their single-
end protocol.
Read lengths were 33 nt for samples N3, T1, T2, and
T 3 ;5 0n tf o rN 2 ,H B R ,a n dU H R ;a n d5 0a n d7 5n tf o r
sample N1. Samples T3 and N1 were each sequenced
over two different Illumina flow cells. We obtained 226
million single-end reads from 8 sequencing runs for
tumors T1, T2, and T3, and matched normals N1, N2,
a n dN 3 .W eo b t a i n e d5 3m i l l i o nr e a d sf o rH B Ra n d6 0
million reads for UHR.
Targeted alignment
We aligned transcripts from RefSeq release 31 to the
human genome build 36.1 using the best alignment
from GMAP to obtain 46,546 alignments. We restricted
our analysis to those well-annotated RefSeq transcripts
starting with “NM_”, or 27,157 alignments. These align-
ments contained 179,909 unique donor sites and
180,874 unique acceptor sites. Sites were often found in
more than one transcript, due to alternative transcripts
in RefSeq. We therefore labeled each donor and accep-
tor site with the set of exons from all alternative tran-
scripts containing that site.
We found that 115,240 donor sites had a potential
TIC acceptor site within 200,000 nt on the same geno-
mic strand, where that site had no associated transcripts
in common with the donor site. Likewise, we found that
108,298 acceptor sites had a potential TIC donor site. A
computer script generated all potential TIC exon-exon
junctions by taking 80 nt upstream and 80 nt down-
stream of all possible TIC donor-acceptor pairs. Pairings
of these sites yielded 2,470,383 possible TIC exon-exon
junctions, each of length 160 nt. To reduce the occur-
rence of false positive alignments, we also generated all
possible intragenic exon-exon junctions from all pairs of
exons within the same transcript, resulting in 1,856,519
potential intragenic exon-exon junctions.
We constructed index files for both the TIC and intra-
genic exon-exon junctions using the GMAP_SETUP
program. We mapped short reads to the artificial exon-
exon junctions using GSNAP (version 2010-07-27),
allowing up to a score of 5 ("-m 5” flag), where mis-
matches count as 1 point and indel gap openings count
as 1 ("-i 1”). We considered a read to be evidence for an
exon-exon junction if it had a unique alignment to a
target with zero or one mismatch and no indels and if
the alignment extended past the midpoint of the target
by a certain overhang amount.
After clustering the alignments by exon-exon junction,
we implemented a filtering process to reduce the inci-
dence of false positives due to poor alignments. We
accepted only clusters that had 11 or more consistent
match positions on both sides of the exon-exon junction
and no consistent patterns of mismatches on either side.
A consistent match position was one that matched in
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sequence alignment.
We also implemented a filtering process to remove false
positives due to homologous genes. We aligned a given
candidate TIC exon-exon junction against each RefSeq
transcript containing one of the exons using GMAP [28].
We constructed the nucleotide fragment corresponding to
the longest overhang observed in each side of the exon-
exon junction. We rejected the TIC candidate if 90% or
more of the splice junction aligned to any component
gene transcript. We also aligned the upstream RefSeq
genes against the downstream genes for possible evidence
of similarity, again using GMAP. If we found any local
alignment having 40 matches within a window of 50 nt,
we also rejected the TIC candidate.
To assess the false discovery rate (FDR) of our analysis
pipeline, we applied a previously developed technique
for estimating the FDR for alternative splicing predic-
tions [20]. For each of our artificial exon-exon junctions,
we removed 5 bp from both the 5
’ and 3
’ exons, at the
- 1 0t o- 6a n dt h e+ 6t o+ 1 0p o s i t i o n sr e l a t i v et ot h e
junction, and applied the same alignment and filtering
steps against these junctions.
All clustering and filtering steps were performed using
computer scripts written in Perl.
Analysis of coding regions and domains
Coding regions and protein sequences for the 5’ and 3’
genes were obtained from the CDS field in the RefSeq
entry for the gene. Chimeras were constructed by con-
catenating component exons from the 5
’ and 3
’ genes. If
the original transcriptional start site (TSS) of the 5
’ gene
was included in the chimera, the coding region and pro-
tein was extended from that TSS. If the chimeric break-
point occurred before the TSS, then the coding region
and protein were predicted computationally from the
longest open reading frame.
Domains were predicted from protein sequences using
hmmscan version 3.0b3 in the HMMER package http://
hmmer.janelia.org, and the Pfam database of protein
domains version 24.0 [50]. A domain was considered
present in the original genes if it had an E-value of 1e-6
or lower in any single position in the protein sequence.
It was considered present in the chimeric protein if it
appeared in the list above the default inclusion thresh-
old, which is based on a per-sequence E-value of 0.01.
The set of chimeric domains was then compared with
each of the domain sets for the original 5
’ and 3
’ pro-
teins. If the original 5
’ or 3
’ protein had no domains,
that relationship was considered “ND” (no domain).
Otherwise, the chimeric set of domains was character-
ized as being either null (no intersection with the origi-
nal domains); a proper, non-empty subset; or covering
all of the original domains.
Spliced alignment
We aligned the reads using GSNAP [27] to human gen-
ome build 36.1, allowing for three mismatches ("-m 3”
flag) and an indel penalty of 1 ("-i 1”), with the SNP-tol-
erance feature ("-V”) enabled for dbSNP version 129
and both novel ("-N 1”) and known splice detection
("-s”) enabled for known splice sites from RefSeq release
31. Subsequent collection and filtering steps were
performed using computer scripts written in Perl.
These alignments were also used for measuring gene
expression levels. Expression was measured in reads per
kilobase per million total reads (RPKM) by counting the
number of reads aligning to exons in a given gene, and
then normalizing by the total length of the exons and
the total number of reads.
Validation of TIC and fusion events
TIC and fusion events were confirmed using TaqMan
assays. For each event, a probe and two sets of forward and
reverse primers were designed and synthesized (IDT, Cor-
alville, IA), and tested in a pilot study using the original
prostate sample that generated the short read providing
evidence for the TIC or fusion event. Primers that gave
good experimental results in the pilot study were selected
for further use in subsequent assays and measurements.
Additional file 7 lists the primers and probes used in the
study, with both sets of primers listed for events where the
pilot study failed to confirm the original event.
The GAPDH control primer and probe set was
obtained from Applied Biosystems. Probes were designed
based on the unique exon junctions formed by fusion
events. Assays were performed using 25 ng RNA per
reaction using the Qiagen QuantiTect Probe RT-PCR kit.
The one step qRT-PCR reaction was performed at 50 deg
for 30 min. and 95 deg for 15 min., followed by 40 cycles
at 94 deg for 15 sec. and 60 deg for 1 min. Data was col-
lected with the ABI PRISM 7000 Sequence Detection
System. Target amount relative to GAPDH was computed
by the comparative CT method [51]. Each qRT-PCR
reaction was performed twice to obtain a mean value and
standard error.
CGH microarray protocols
Genomic DNA was labeled and hybridized to Agilent
CGH 244K microarrays (Santa Clara, CA) using the
manufacturer’s recommended protocols. Human male
genomic DNA (Promega P/N G1471) was used as refer-
ence. Individual log2 ratios of background-subtracted
signal intensities were obtained from the Agilent Feature
Extraction software version 9.5.
Data availability
Sequencing and microarray data used in this study have
been deposited with the NCBI Gene Expression
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Page 20 of 22Omnibus database [52] and are accessible through GEO
Series accession number GSE24284, with the CGH
microarray data accessible through SubSeries accession
number GSE24282 and the sequencing data accessible
through SubSeries accession number GSE24283.
Additional material
Additional file 1: TIC events found by targeted detection approach.
Additional file 2: Supporting reads for TIC events.
Additional file 3: TICs with intervening exons.
Additional file 4: Distant fusions found by spliced alignment
approach.
Additional file 5: Supporting reads for distant fusions.
Additional file 6: Sample information and pathology evaluation.
Additional file 7: Primers and probes used for qRT-PCR
measurements.
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